首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Identification of small molecule sphingomyelin synthase inhibitors
【24h】

Identification of small molecule sphingomyelin synthase inhibitors

机译:小分子鞘磷脂合酶抑制剂的鉴定

获取原文
获取原文并翻译 | 示例
       

摘要

Sphingomyelin synthase (SMS), which catalyzes ceramide as one of the substrates to produce sphingomyelin, is a critical factor in the sphingolipid biosynthesis pathway. Recent studies indicated that SMS could serve as a novel potential drug target for the treatment of various metabolic diseases such as insulin resistance and atherosclerosis. However, very few small-molecule inhibitors of SMS are known. In this study, we performed structure-based virtual screening in combination with chemical synthesis and bioassay and discovered a class of small-molecule SMS inhibitors. The most potent compound exhibited an IC50 value lower than 20 μM in an in vitro enzymatic assay. To the best of our knowledge, this is the first time that small-molecule SMS inhibitors with potency close to the micromolar range are publicly revealed. The structure-activity relationship demonstrated by this class of compounds provides insights into the structural features that are essential for effective SMS inhibition.
机译:鞘磷脂合酶(SMS)催化神经酰胺作为产生鞘磷脂的底物之一,是鞘脂生物合成途径中的关键因素。最近的研究表明,SMS可以作为治疗各种新陈代谢疾病(例如胰岛素抵抗和动脉粥样硬化)的新型潜在药物靶标。但是,很少有SMS的小分子抑制剂。在这项研究中,我们结合化学合成和生物测定进行了基于结构的虚拟筛选,并发现了一类小分子SMS抑制剂。在体外酶法测定中,最有效的化合物的IC50值低于20μM。据我们所知,这是首次公开展示效力接近微摩尔范围的小分子SMS抑制剂。这类化合物证明的结构活性关系提供了有效抑制SMS必不可少的结构特征的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号